论文部分内容阅读
在1993年7月至1996年2月,274例新诊断的APL患者被登记加入GIMEMA-AIEOP多中心协作组,对AIDA方案进行了研究。诊断按FAB分类,包括AML中的M3和M3变异型(M3V)。所有病例均经染色体核型或PML/RAR-a的逆转录多聚酶链反应(RT-PCR)的检查,证实有t(15;17)损害及细胞遗传学证据。AIDA方案包括口服ATRA45mg/m~2·d至
From July 1993 to February 1996, 274 newly diagnosed APL patients were enrolled in the GIMEMA-AIEOP multi-center collaboration group to study the AIDA protocol. Diagnosis is classified by FAB and includes M3 and M3 variants (M3V) in AML. All cases were examined by reverse transcriptase polymerase chain reaction (RT-PCR) with karyotype or PML/RAR-a, confirming t(15;17) damage and cytogenetic evidence. The AIDA program includes oral ATRA 45mg/m~2d to